Microfluidic Manufacture of Lipid-Based Nanomedicines

Nanoparticulate technologies have revolutionized drug delivery allowing for passive and active targeting, altered biodistribution, controlled drug release (temporospatial or triggered), enhanced stability, improved solubilization capacity, and a reduction in dose and adverse effects. However, their...

Повний опис

Збережено в:
Бібліографічні деталі
Автори: Karim Osouli-Bostanabad (Автор), Sara Puliga (Автор), Dolores R. Serrano (Автор), Andrea Bucchi (Автор), Gavin Halbert (Автор), Aikaterini Lalatsa (Автор)
Формат: Книга
Опубліковано: MDPI AG, 2022-09-01T00:00:00Z.
Предмети:
Онлайн доступ:Connect to this object online.
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cf650d189bd74a10b74d2f59e3b25c84
042 |a dc 
100 1 0 |a Karim Osouli-Bostanabad  |e author 
700 1 0 |a Sara Puliga  |e author 
700 1 0 |a Dolores R. Serrano  |e author 
700 1 0 |a Andrea Bucchi  |e author 
700 1 0 |a Gavin Halbert  |e author 
700 1 0 |a Aikaterini Lalatsa  |e author 
245 0 0 |a Microfluidic Manufacture of Lipid-Based Nanomedicines 
260 |b MDPI AG,   |c 2022-09-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics14091940 
500 |a 1999-4923 
520 |a Nanoparticulate technologies have revolutionized drug delivery allowing for passive and active targeting, altered biodistribution, controlled drug release (temporospatial or triggered), enhanced stability, improved solubilization capacity, and a reduction in dose and adverse effects. However, their manufacture remains immature, and challenges exist on an industrial scale due to high batch-to-batch variability hindering their clinical translation. Lipid-based nanomedicines remain the most widely approved nanomedicines, and their current manufacturing methods remain discontinuous and face several problems such as high batch-to-batch variability affecting the critical quality attributes (CQAs) of the product, laborious multistep processes, need for an expert workforce, and not being easily amenable to industrial scale-up involving typically a complex process control. Several techniques have emerged in recent years for nanomedicine manufacture, but a paradigm shift occurred when microfluidic strategies able to mix fluids in channels with dimensions of tens of micrometers and small volumes of liquid reagents in a highly controlled manner to form nanoparticles with tunable and reproducible structure were employed. In this review, we summarize the recent advancements in the manufacturing of lipid-based nanomedicines using microfluidics with particular emphasis on the parameters that govern the control of CQAs of final nanomedicines. The impact of microfluidic environments on formation dynamics of nanomaterials, and the application of microdevices as platforms for nanomaterial screening are also discussed. 
546 |a EN 
690 |a nanomedicine 
690 |a microfluidics 
690 |a liposomes 
690 |a manufacture 
690 |a engineering 
690 |a scale-up 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 14, Iss 9, p 1940 (2022) 
787 0 |n https://www.mdpi.com/1999-4923/14/9/1940 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/cf650d189bd74a10b74d2f59e3b25c84  |z Connect to this object online.